Hemminki, Kari
Kanerva, Anna
Försti, Asta
Hemminki, Akseli
Funding for this research was provided by:
European Commission (856620)
Article History
Received: 8 November 2021
Accepted: 8 April 2022
First Online: 26 April 2022
Declarations
:
: Aggregated data from a publicly accessible database were used posing no ethical issues.
: Not applicable.
: A.H. is shareholder in Targovax ASA. A.H. is employee and shareholder in TILT Biotherapeutics Ltd. Other authors declared no conflict of interest.